Advanced search
Publication Cover
International Journal of General Medicine Volume 13, 2020 - Issue
Submit an article Journal homepage
91
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Evaluation of Serum Level of FGF23 and 1,25(OH)2D3 in Primary Hyperparathyroidism Patients Before and After Parathyroidectomy

Solmaz Hassani1 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
,
Mozhgan Afkhamizadeh1 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, IranORCID Iconhttps://orcid.org/0000-0002-0998-3694
ORCID Icon,
Ali Teimouri2 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, IranORCID Iconhttps://orcid.org/0000-0001-5900-4493
ORCID Icon,
Mona Najaf Najafi3 Clinical Research Development Unit, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IranORCID Iconhttps://orcid.org/0000-0002-2646-7720
ORCID Icon,
Leila Vazifeh Mostaan4 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, IranORCID Iconhttps://orcid.org/0000-0001-8322-906X
ORCID Icon &
Masoud Mohebbi1 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, IranCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2285-6809
ORCID Icon
Pages 289-295 | Published online: 11 Jun 2020

References

  • Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(5):593–607. doi:10.1016/j.beem.2018.09.00430449543
  • Madkhali T, Alhefdhi A, Chen H, Elfenbein D. Primary hyperparathyroidism. Ulus Cerrahi Derg. 2016;32(1):58–66. doi:10.5152/UCD.2015.303226985167
  • Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1–19. doi:10.1007/s00198-016-3716-2
  • Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ. 2012;345:e6390. doi:10.1136/bmj.e639023080543
  • Boehm BO, Rosinger S, Belyi D, Dietrich JW. The parathyroid as a target for radiation damage. N Engl J Med. 2011;365(7):676–678. doi:10.1056/NEJMc110498221848480
  • Vaidya A, Curhan GC, Paik JM, Kronenberg H, Taylor EN. Hypertension, antihypertensive medications, and risk of incident primary hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(6):2396–2404. doi:10.1210/jc.2015-161925885946
  • Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol. 2009;160(2):317–323. doi:10.1530/EJE-08-062019001061
  • Suliburk JW, Perrier ND. Primary hyperparathyroidism. Oncologist. 2007;12(6):644–653. doi:10.1634/theoncologist.12-6-64417602056
  • Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NAT. Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol. 2012;166(1):55–60. doi:10.1530/EJE-11-052321984611
  • Erben RG. Physiological actions of fibroblast growth factor-23. Front Endocrinol (Lausanne). 2018;9:267. doi:10.3389/fendo.2018.0026729892265
  • Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131–155. doi:10.1152/physrev.00002.201122298654
  • Perwad F, Azam N, Zhang MYH, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146(12):5358–5364. doi:10.1210/en.2005-077716123154
  • Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004;44(3):481–487. doi:10.1016/S0272-6386(04)00817-015332221
  • Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18(10):2683–2688. doi:10.1681/ASN.200607078317855636
  • Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004;89(9):4489–4492. doi:10.1210/jc.2004-072415356053
  • McDow AD, Sippel RS. Should symptoms be considered an indication for parathyroidectomy in primary hyperparathyroidism? Clin Med Insights Endocrinol Diabetes. 2018;11:1179551418785135. doi:10.1177/117955141878513530013413
  • Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the heart and soul study. Am J Kidney Dis. 2011;58(5):737–745. doi:10.1053/j.ajkd.2011.06.01121855188
  • Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154(1):93–99. doi:10.1530/eje.1.0205316381997
  • Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004;151(1):55–60. doi:10.1530/eje.0.151005515248822
  • Tebben PJ, Singh RJ, Clarke BL, Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc. 2004;79(12):1508–1513. doi:10.4065/79.12.150815595334

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.